Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Tumor growth and chemo response may be predicted by mathematical model

Tumor growth and chemo response may be predicted by mathematical model

May 19, 2009

The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston.

In spite of extensive experimental and clinical studies, the process of cancer growth is not well understood. Tumors are complex systems, with changes at the molecular and cellular levels influencing shape and behavior in sometimes unpredictable ways. New research by a scientist in mathematical oncology at the UT Health Science Center at Houston suggests that mathematical modeling based on data from the molecular and cellular levels could shed light on tumor development and lead to better treatments.




Cancer is the second most common cause of death in the United States, exceeded only by heart disease, according to the American Cancer Society.

At the 100th annual meeting of the American Association for Cancer Research in Denver this spring, Vittorio Cristini, Ph.D., an associate professor of health informatics at The University of Texas School of Health Information Sciences at Houston, demonstrated the predictability of tumor growth in brain cancer and chemotherapy response in breast cancer. Findings appear in two different papers in the May 15 print issue of the association's peer-reviewed journal Cancer Research.

The mathematical model developed by Cristini's lab works by defining tumor biologic and molecular properties relating to laboratory and clinical observations of cancers. In this model, the behavior of cancer cells and their surroundings is linked to tumor growth, shape and treatment response.

"The central finding of this work is that tumor growth and invasion are not erratic or unpredictable, or solely explained through genomic and molecular events, but rather are predictable processes obeying biophysical laws," the authors wrote in the paper addressing predictability of tumor growth in brain cancer.

Tumors obtain nutrients and oxygen by harnessing the surrounding blood vessels and making new vessels. Since there typically aren't enough nutrients and oxygen to support tumor cells, an uneven distribution of these substances is created inside and around the tumor mass, Cristini said.

The research of Cristini and colleagues, who worked in collaboration with Elaine L. Bearer, M.D., Ph.D., professor at the Brown School of Medicine, suggests that tumor growth and invasion could be predicted by using biophysical laws that link the effects of the uneven distribution of cell nutrients and oxygen to overall tumor behavior.

For different values of the input parameters, the model consistently reproduced the patterns of tumor invasion observed in experiments and in patient tumors, Cristini said. The patterns were regulated by changes in cellular characteristics, causing more aggressive tumor cells to invade the healthy tissue. As cancer cells invade and replicate themselves, they make the tumor shape unstable and more invasive. The model correctly predicted the different types of invasion under a variety of conditions.

The model further predicted that the different forms of cancer invasion correspond to different stages of tumor progression, Cristini said. In regions of low oxygen, these changes may include a slowdown in cell replication and heightened cell migration, which can result in a "single-cell file" invasion pattern. As cells aggregate in regions that have better access to nutrients and oxygen, migration is lessened and cell replication is resumed. This leads to the formation of wave-like patterns of cell rearrangements at the tumor boundary and the formation of round infiltrative "fingers" that can detach from the tumor as clusters of cells.

In the second paper, working in collaboration with Mary Edgerton, M.D., Ph.D., associate professor of pathology at The University of Texas M. D. Anderson Cancer Center, the researchers used the mathematical model to successfully predict the effects of doxorubicin on breast tumor growth. The model incorporates information gleaned from cancer cells grown in the laboratory to determine whether a prescribed drug will reach the tumor in sufficient quantities to kill the malignant cells. "We seek to improve the precision of prescribing chemotherapeutic drugs, since it is sometimes hard to tell which will work and which will not, and what the optimal dose is for a particular patient," said Hermann Frieboes, Ph.D., lead author of the chemotherapy study and a post doctoral fellow at the UT School of Health Information Sciences.

In the not-too-distant future, the mathematical model could help design therapies in which the molecular and cellular characteristics of a patient's tumor are manipulated, Cristini said. This could decrease the spread of the tumor and help surgeons remove growths more effectively. This manipulation could also increase the susceptibility of tumors to chemotherapy, he added. The model could augment efforts to predict drug response, which currently include removing a tiny sample of cancer tissue and testing the response of its cells to cancer drugs in a laboratory situation before the patient starts treatment. By basing the model input parameters on specific patient data, the treatment outcomes could be predicted better.

The two studies, titled "Multiparameter computational modeling of tumor invasion" and "Prediction of drug response in breast cancer using integrative experimental/computational modeling," received support from The Cullen Trust for Health Care, the National Science Foundation, the National Institutes of Health and the U.S. Department of Defense.

Cristini's co-authors also include Mauro Ferrari, Ph.D., director of the nanomedicine division at the UT Health Science Center at Houston and president of the Alliance for NanoHealth, Houston; and two members of the faculty of the University of California, Irvine, John Lowengrub, Ph.D., and John Fruehauf, M.D., Ph.D.

UT Health Science Center at Houston



Related Tumor Growth Current Events and Tumor Growth News Articles Tumor Growth Current Events and Tumor Growth News RSS Tumor Growth Current Events and Tumor Growth News RSS
Laser therapy can aggravate skin cancer
High irradiances of low-level laser therapy (LLLT) should not be used over melanomas.

Common pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

Cancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

Researchers 'notch' a victory toward new kind of cancer drug
Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed.

New mechanism explains how the body prevents formation of blood vessels
Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels.

CSHL study shows that some malignant tumors can be shut down after all
Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53.

Hundreds of genes distinguish patients likely to survive advanced melanoma
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs.

1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.

Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

Researchers use drug-radiation combo to eradicate lung cancer
Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.
More Tumor Growth Current Events and Tumor Growth News Articles
Growth Factors and Tumor Promotion: Implications for Risk Assessment

Growth Factors and Tumor Promotion: Implications for Risk Assessment
by Tex.) International Conference on Carcinogenesis and Risk Assessment (7th : 1993 : Austin (Author), Thomas J. Slaga (Editor), Robert Leboeuf (Editor), Henry Pitot (Editor), R. Michael McClain (Editor)

Hoffman LaRoche, Inc., Nutley, New Jersey. Proceedings of the Seventh International Conference on Carcinogenesis and Risk Assessment held December 1-4, 1993, in Austin, Texas.

  No. 571(Tumors, Growths) 1 oz
by PROGRESSIVE LABS



Charlie Rose with Anthony Robbins (July 19, 2000)

Charlie Rose with Anthony Robbins (July 19, 2000)

Motivational speaker Anthony Robbins on his unusual career advising everyone from Andre Agassi and President Clinton to the IBM Corporation and the United States Army and the launch of his new website, www.dreamlife.com.

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

Intracranial Tumor Canvas Print - Canvas Art

Intracranial Tumor Canvas Print - Canvas Art
by FineArtAmerica.com

This is a beautiful stretched-canvas art print wrapped on 2.5" thick stretcher bars. The print is professionally printed, assembled, and shipped within 2 - 3 business days from our production facility in North Carolina and arrives ready-to-hang on your wall. FineArtAmerica.com is home to more than 20,000 artists from all over the world who entrust us to fulfill their print orders online. We offer a 30-day money-back guarantee on every print that we sell and look forward to helping you select your next piece.

Olympian Labs Ip-6, Inositol Hexaphosphate

Olympian Labs Ip-6, Inositol Hexaphosphate
by Olympian Labs

Inositol hexaphosphate is a sugar molecule attached to six phosphate molecules. It is found throughout nature, in wheat and rice bran, legumes such as soybeans and virtually every kind of mammalian cell. It plays an important role in regulating vital cellular functions including cell proliferation and differentiation.

There has been research on human liver cancer cells that were treated with inositol hexaphosphate and transplanted into mice. They found that inositol hexaphosphate slowed or stopped the growth of liver cancer cells and shrank existing tumors three- to four-fold. Inositol hexaphosphate does not kill cancer cells - it tames them and makes them behave like normal cells. Inositol hexaphosphate decreases proliferation of cancer cells and causes them to differentiate,...

Cancer Immunotherapy: Immune Suppression and Tumor Growth

Cancer Immunotherapy: Immune Suppression and Tumor Growth
by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor)

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait...

  Two drugs halted tumor growth in lung cancer.(Clinical Rounds): An article from: Family Practice News
by Erik L. Goldman (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2004. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Two drugs halted tumor growth in lung cancer.(Clinical Rounds)
Author: Erik L. Goldman
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2004
Publisher: International Medical News Group
Volume: 34 Issue: 17 Page: 60(1)

Distributed by Thomson...

  Peregrine's phospholipid-targeted antibodies fused wth cytokines reduce tumor growth.: An article from: BIOTECH Patent News
by Gale Reference Team (Author)

This digital document is an article from BIOTECH Patent News, published by Thomson Gale on September 1, 2006. The length of the article is 654 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Peregrine's phospholipid-targeted antibodies fused wth cytokines reduce tumor growth.
Author: Gale Reference Team
Publication: BIOTECH Patent News (Newsletter)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 20 Issue: 9

Distributed by Thomson...

  Mechanism of tumor growth in crowngall
by Erwin F Smith (Author)



  Influence of the Host on Tumor Development (Cancer Growth and Progression)
by Ronald B. Herberman (Editor)

X

© 2009 BrightSurf.com